Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 28, 10, (2183-2193), 10.1038/s41591-022-01919-8)

Andrew Feigin; Elizabeth E. Evans; Terrence L. Fisher; John E. Leonard; Ernest S. Smith; Alisha Reader; Vikas Mishra; Richard Manber; Kimberly A. Walters; Lisa Kowarski; David Oakes; Eric Siemers; Karl D. Kieburtz; Maurice Zauderer; Elise Kayson; Jody Goldstein; Richard Barbano; Karen Marder; Praveen Dayalu; Herminia Diana Rosas; Sandra Kostyk; John Kamholz; Brad Racette; Jee Bang; Daniel Claassen; Katherine McDonell; Stewart Factor; Francis Walker; Clarisse Goas; Joanne Wojcieszek; Lynn A. Raymond; Jody Corey-Bloom; Victor Sung; Marissa Dean; Michael Geshwind; Alexandra Nelson; Samuel Frank; Kathrin LaFaver; Andrew Duker; Lawrence Elmer; Ali Samii; Yi Han Lin; Sylvain Chouinard; Lauren Seeberger; Burton Scott; James Boyd; Nikolaus McFarland; Erin Furr Stimming; Oksana Suchowersky; Claudia Testa; Karen Anderson

doi:10.1038/s41591-022-02070-0

Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 28, 10, (2183-2193), 10.1038/s41591-022-01919-8)

Andrew Feigin, Elizabeth E. Evans, Terrence L. Fisher, John E. Leonard, Ernest S. Smith, Alisha Reader, Vikas Mishra, Richard Manber, Kimberly A. Walters, Lisa Kowarski, David Oakes, Eric Siemers, Karl D. Kieburtz, Maurice Zauderer, Elise Kayson, Jody Goldstein, Richard Barbano, Karen Marder, Praveen Dayalu, Herminia Diana RosasSandra Kostyk, John Kamholz, Brad Racette, Jee Bang, Daniel Claassen, Katherine McDonell, Stewart Factor, Francis Walker, Clarisse Goas, Joanne Wojcieszek, Lynn A. Raymond, Jody Corey-Bloom, Victor Sung, Marissa Dean, Michael Geshwind, Alexandra Nelson, Samuel Frank, Kathrin LaFaver, Andrew Duker, Lawrence Elmer, Ali Samii, Yi Han Lin, Sylvain Chouinard, Lauren Seeberger, Burton Scott, James Boyd, Nikolaus McFarland, Erin Furr Stimming, Oksana Suchowersky, Claudia Testa, Karen Anderson

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the version of this article initially published, in the first and final paragraphs of the Results section, the dosing schedule for pepinemab administration was described in error as “four times per week” instead of “every four weeks,” while in the Fig. 4b color key, the bottom, dark green key now reading “Much improved” appeared originally as “Minimally improved.” The errors have been corrected in the HTML and PDF versions of the article.

Original language	English (US)
Pages (from-to)	606
Number of pages	1
Journal	Nature medicine
Volume	30
Issue number	2
DOIs	https://doi.org/10.1038/s41591-022-02070-0
State	Published - Feb 2024

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1038/s41591-022-02070-0

Fingerprint

Dive into the research topics of 'Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 28, 10, (2183-2193), 10.1038/s41591-022-01919-8)'. Together they form a unique fingerprint.

Cite this

Feigin, A., Evans, E. E., Fisher, T. L., Leonard, J. E., Smith, E. S., Reader, A., Mishra, V., Manber, R., Walters, K. A., Kowarski, L., Oakes, D., Siemers, E., Kieburtz, K. D., Zauderer, M., Kayson, E., Goldstein, J., Barbano, R., Marder, K., Dayalu, P., ... Anderson, K. (2024). Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 28, 10, (2183-2193), 10.1038/s41591-022-01919-8). Nature medicine, 30(2), 606. https://doi.org/10.1038/s41591-022-02070-0

Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 28, 10, (2183-2193), 10.1038/s41591-022-01919-8). / Feigin, Andrew; Evans, Elizabeth E.; Fisher, Terrence L. et al.
In: Nature medicine, Vol. 30, No. 2, 02.2024, p. 606.

Research output: Contribution to journal › Comment/debate › peer-review

Feigin, A, Evans, EE, Fisher, TL, Leonard, JE, Smith, ES, Reader, A, Mishra, V, Manber, R, Walters, KA, Kowarski, L, Oakes, D, Siemers, E, Kieburtz, KD, Zauderer, M, Kayson, E, Goldstein, J, Barbano, R, Marder, K, Dayalu, P, Rosas, HD, Kostyk, S, Kamholz, J, Racette, B, Bang, J, Claassen, D, McDonell, K, Factor, S, Walker, F, Goas, C, Wojcieszek, J, Raymond, LA, Corey-Bloom, J, Sung, V, Dean, M, Geshwind, M, Nelson, A, Frank, S, LaFaver, K, Duker, A, Elmer, L, Samii, A, Lin, YH, Chouinard, S, Seeberger, L, Scott, B, Boyd, J, McFarland, N, Stimming, EF, Suchowersky, O, Testa, C & Anderson, K 2024, 'Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 28, 10, (2183-2193), 10.1038/s41591-022-01919-8)', Nature medicine, vol. 30, no. 2, pp. 606. https://doi.org/10.1038/s41591-022-02070-0

@article{d212f452b3e042db9a95ff24e0e4037e,

title = "Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington{\textquoteright}s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 28, 10, (2183-2193), 10.1038/s41591-022-01919-8)",

abstract = "In the version of this article initially published, in the first and final paragraphs of the Results section, the dosing schedule for pepinemab administration was described in error as “four times per week” instead of “every four weeks,” while in the Fig. 4b color key, the bottom, dark green key now reading “Much improved” appeared originally as “Minimally improved.” The errors have been corrected in the HTML and PDF versions of the article.",

author = "Andrew Feigin and Evans, {Elizabeth E.} and Fisher, {Terrence L.} and Leonard, {John E.} and Smith, {Ernest S.} and Alisha Reader and Vikas Mishra and Richard Manber and Walters, {Kimberly A.} and Lisa Kowarski and David Oakes and Eric Siemers and Kieburtz, {Karl D.} and Maurice Zauderer and Elise Kayson and Jody Goldstein and Richard Barbano and Karen Marder and Praveen Dayalu and Rosas, {Herminia Diana} and Sandra Kostyk and John Kamholz and Brad Racette and Jee Bang and Daniel Claassen and Katherine McDonell and Stewart Factor and Francis Walker and Clarisse Goas and Joanne Wojcieszek and Raymond, {Lynn A.} and Jody Corey-Bloom and Victor Sung and Marissa Dean and Michael Geshwind and Alexandra Nelson and Samuel Frank and Kathrin LaFaver and Andrew Duker and Lawrence Elmer and Ali Samii and Lin, {Yi Han} and Sylvain Chouinard and Lauren Seeberger and Burton Scott and James Boyd and Nikolaus McFarland and Stimming, {Erin Furr} and Oksana Suchowersky and Claudia Testa and Karen Anderson",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022.",

year = "2024",

month = feb,

doi = "10.1038/s41591-022-02070-0",

language = "English (US)",

volume = "30",

pages = "606",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Publisher Correction

T2 - Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 28, 10, (2183-2193), 10.1038/s41591-022-01919-8)

AU - Feigin, Andrew

AU - Evans, Elizabeth E.

AU - Fisher, Terrence L.

AU - Leonard, John E.

AU - Smith, Ernest S.

AU - Reader, Alisha

AU - Mishra, Vikas

AU - Manber, Richard

AU - Walters, Kimberly A.

AU - Kowarski, Lisa

AU - Oakes, David

AU - Siemers, Eric

AU - Kieburtz, Karl D.

AU - Zauderer, Maurice

AU - Kayson, Elise

AU - Goldstein, Jody

AU - Barbano, Richard

AU - Marder, Karen

AU - Dayalu, Praveen

AU - Rosas, Herminia Diana

AU - Kostyk, Sandra

AU - Kamholz, John

AU - Racette, Brad

AU - Bang, Jee

AU - Claassen, Daniel

AU - McDonell, Katherine

AU - Factor, Stewart

AU - Walker, Francis

AU - Goas, Clarisse

AU - Wojcieszek, Joanne

AU - Raymond, Lynn A.

AU - Corey-Bloom, Jody

AU - Sung, Victor

AU - Dean, Marissa

AU - Geshwind, Michael

AU - Nelson, Alexandra

AU - Frank, Samuel

AU - LaFaver, Kathrin

AU - Duker, Andrew

AU - Elmer, Lawrence

AU - Samii, Ali

AU - Lin, Yi Han

AU - Chouinard, Sylvain

AU - Seeberger, Lauren

AU - Scott, Burton

AU - Boyd, James

AU - McFarland, Nikolaus

AU - Stimming, Erin Furr

AU - Suchowersky, Oksana

AU - Testa, Claudia

AU - Anderson, Karen

PY - 2024/2

Y1 - 2024/2

N2 - In the version of this article initially published, in the first and final paragraphs of the Results section, the dosing schedule for pepinemab administration was described in error as “four times per week” instead of “every four weeks,” while in the Fig. 4b color key, the bottom, dark green key now reading “Much improved” appeared originally as “Minimally improved.” The errors have been corrected in the HTML and PDF versions of the article.

AB - In the version of this article initially published, in the first and final paragraphs of the Results section, the dosing schedule for pepinemab administration was described in error as “four times per week” instead of “every four weeks,” while in the Fig. 4b color key, the bottom, dark green key now reading “Much improved” appeared originally as “Minimally improved.” The errors have been corrected in the HTML and PDF versions of the article.

UR - http://www.scopus.com/inward/record.url?scp=85139191001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85139191001&partnerID=8YFLogxK

U2 - 10.1038/s41591-022-02070-0

DO - 10.1038/s41591-022-02070-0

M3 - Comment/debate

C2 - 36195687

AN - SCOPUS:85139191001

SN - 1078-8956

VL - 30

SP - 606

JO - Nature medicine

JF - Nature medicine

IS - 2

ER -

Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 28, 10, (2183-2193), 10.1038/s41591-022-01919-8)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this